The Mediating Role of Endocrine Factors in the Positive Relationship Between Fat Mass and Bone Mineral Content in Children Aged 9-11 Years: The Physical Activity and Nutrition in Children Study.
DXA (dual-energy X-ray absorptiometry)
adiponectin
adiposity
insulin
leptin
paediatric
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
01
2022
accepted:
21
02
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
We aimed to investigate whether the relationship between fat mass and bone mineral content (BMC) is mediated by insulin, leptin, adiponectin, dehydroepiandrosterone sulphate, testosterone and estradiol in children aged 9-11 years. We utilised cross-sectional data from the Physical Activity and Nutrition in Children study (n = 230 to 396; 112 to 203 girls). Fat mass and BMC were assessed with dual-energy X-ray absorptiometry. Endocrine factors were assessed from fasted blood samples. We applied the novel 4-way decomposition method to analyse associations between fat mass, endocrine factors, and BMC. Fat mass was positively associated with BMC in girls (ß = 0.007 to 0.015, 95% confidence interval (CI) 0.005 to 0.020) and boys (ß = 0.009 to 0.015, 95% CI 0.005 to 0.019). The relationship between fat mass and BMC was mediated by free leptin index in girls (ß = -0.025, 95% CI -0.039 to -0.010) and boys (ß = -0.014, 95% CI -0.027 to -0.001). The relationship between fat mass and BMC was partially explained by mediated interaction between fat mass and free leptin index in boys (ß = -0.009, 95% CI -0.013 to -0.004) and by interaction between fat mass and adiponectin in girls (ß = -0.003, 95% CI -0.006 to -0.000). At greater levels of adiponectin and free leptin index, the fat mass and BMC relationship becomes less positive in girls and boys respectively. The positive association between fat mass with BMC was largely not explained by the endocrine factors we assessed. [https://clinicaltrials.gov/ct2/show/NCT01803776], identifier NCT01803776.
Identifiants
pubmed: 35399927
doi: 10.3389/fendo.2022.850448
pmc: PMC8987010
doi:
Substances chimiques
Adiponectin
0
Leptin
0
Banques de données
ClinicalTrials.gov
['NCT01803776']
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
850448Informations de copyright
Copyright © 2022 Constable, Vlachopoulos, Barker, Moore, Soininen, Haapala, Väistö, Jääskeläinen, Voutilainen, Auriola, Häkkinen, Laitinen and Lakka.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocrinology. 2009 Aug;150(8):3603-10
pubmed: 19406946
J Clin Endocrinol Metab. 2007 Apr;92(4):1517-23
pubmed: 17264180
Pediatr Res. 1997 Oct;42(4):484-8
pubmed: 9380440
J Clin Endocrinol Metab. 1997 Jul;82(7):2148-52
pubmed: 9215286
Steroids. 2009 Mar;74(3):296-305
pubmed: 18992761
J Clin Endocrinol Metab. 2012 Jun;97(6):2068-76
pubmed: 22492875
Nutrition. 2020 Feb;70:110489
pubmed: 31655471
J Clin Endocrinol Metab. 1993 Dec;77(6):1629-35
pubmed: 8263151
Ann Med. 2011 May;43(3):235-48
pubmed: 20854213
Arch Biochem Biophys. 2010 Nov 1;503(1):20-7
pubmed: 20599663
Int J Obes (Lond). 2014 Sep;38 Suppl 2:S39-47
pubmed: 25376219
J Clin Endocrinol Metab. 2019 Mar 1;104(3):892-899
pubmed: 30312423
Steroids. 2015 Jul;99(Pt A):11-5
pubmed: 25555470
J Bone Miner Res. 2009 Mar;24(3):522-33
pubmed: 19016587
J Pharm Biomed Anal. 2018 Apr 15;152:165-172
pubmed: 29414008
Bone. 2018 Mar;108:106-114
pubmed: 29307776
PLoS One. 2017 Mar 21;12(3):e0173874
pubmed: 28323845
J Clin Endocrinol Metab. 1997 Sep;82(9):2904-10
pubmed: 9284717
Osteoporos Int. 2001;12(10):887-94
pubmed: 11716194
J Clin Endocrinol Metab. 2010 Apr;95(4):1690-8
pubmed: 20194709
Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E735-45
pubmed: 16215165
Eur J Endocrinol. 2004 Aug;151 Suppl 1:S87-91
pubmed: 15339251
Am J Clin Nutr. 2013 Feb;97(2):318-25
pubmed: 23283497
J Clin Endocrinol Metab. 2002 Oct;87(10):4587-94
pubmed: 12364439
Clin Chem Lab Med. 2002 Nov;40(11):1151-60
pubmed: 12521235
Osteoporos Int. 2016 Apr;27(4):1281-1386
pubmed: 26856587
Pediatr Diabetes. 2012 Feb;13(1):1-5
pubmed: 21545675
N Engl J Med. 2004 Sep 2;351(10):987-97
pubmed: 15342807
Am J Clin Nutr. 2004 Aug;80(2):514-23
pubmed: 15277178
Annu Rev Public Health. 2016;37:17-32
pubmed: 26653405
Bone. 2011 Feb;48(2):189-96
pubmed: 20932948
Epidemiology. 2014 Sep;25(5):749-61
pubmed: 25000145
Clin Endocrinol Metab. 1986 Aug;15(3):411-51
pubmed: 3533329
Int J Epidemiol. 2018 Nov 16;:
pubmed: 30452641
J Bone Miner Res. 2010 Oct;25(10):2212-20
pubmed: 20499348
J Clin Densitom. 2013 Oct-Dec;16(4):562-9
pubmed: 23452871
J Clin Endocrinol Metab. 2006 Jul;91(7):2534-41
pubmed: 16621904
J Clin Endocrinol Metab. 1975 Nov;41(5):894-904
pubmed: 127002
J Clin Endocrinol Metab. 2005 Apr;90(4):1925-8
pubmed: 15634720
Eur J Endocrinol. 2001 Jul;145(1):43-51
pubmed: 11415851
J Obes Metab Syndr. 2019 Mar;28(1):4-17
pubmed: 31089575
Obesity (Silver Spring). 2011 Jun;19(6):1259-64
pubmed: 21311512
Curr Osteoporos Rep. 2020 Aug;18(4):388-400
pubmed: 32529456
Am J Clin Nutr. 2004 Oct;80(4):966-72
pubmed: 15447907
J Clin Endocrinol Metab. 2007 Jan;92(1):143-7
pubmed: 17047019
Horm Res. 2009;72(2):82-7
pubmed: 19690425
Osteoporos Int. 2012 Mar;23(3):937-47
pubmed: 21562873
Pediatr Obes. 2012 Aug;7(4):284-94
pubmed: 22715120
Ann Pediatr Endocrinol Metab. 2018 Jun;23(2):62-69
pubmed: 29969876
Expert Rev Endocrinol Metab. 2010 May;5(3):323-325
pubmed: 30861685